Amgen Inc.

AMGN

US0311621009

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:16:05 2025-01-23 am EST			5-day change	1st Jan Change
272.90 ^USD	-0.20%		+1.42%	+4.84%

Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT
Jan. 17	Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	MT

Deutsche Bank Lowers Amgen Price Target to $285 From $305, Maintains Hold Rating

December 02, 2024 at 07:35 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Amgen Inc.

Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Amgen Says Lumakras With Vectibix Approved by FDA for Metastatic Colorectal Cancer	Jan. 17	MT
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks	Jan. 17	MT
Amgen Inc. Announces FDA Approves LUMAKRAS® in Combination with Vectibix® (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer	Jan. 17	CI
Amgen Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 03:00 PM	Jan. 13
Wells Fargo Cuts Price Target on Amgen to $280 From $335, Maintains Equalweight Rating	Jan. 10	MT
Goldman Sachs Adjusts Price Target on Amgen to $370 From $375, Maintains Buy Rating	Jan. 08	MT
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement with Amgen on Etakafusp Alfa in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer	Jan. 08	CI
Truist Lowers Price Target on Amgen to $298 From $333, Keeps Hold Rating	Jan. 08	MT
RBC Trims Price Target on Amgen to $324 From $330, Keeps Outperform Rating	Jan. 07	MT
Amgen?s IMDYLLTRA Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom	Jan. 06	CI
European Equities Close Mostly Higher in Tuesday Trading; EU Withholds Over $1 Billion From Hungary	Dec. 31	MT
Amgen's Tarlatamab Approved by UK Regulator to Treat Lung Cancer	Dec. 31	MT
Sector Update: Health Care Stocks Advance Late Afternoon	Dec. 23	MT
Sector Update: Health Care	Dec. 23	MT
Eli Lilly, Amgen Sue HHS for Unlawful Certifications of Drug Discount Program Recipients	Dec. 23	MT
Lilly, Amgen Sue HHS Over Certification of Drug Discount Program Recipients	Dec. 23	MT
Top Midday Stories: Novo Nordisk Shares Drop After Obesity Treatment Falls Short of Expectations; CFPB Sues 3 Big Banks Over Alleged Zelle Fraud	Dec. 20	MT
Amgen, Eli Lilly, Viking Therapeutics Shares Rise Pre-Bell After Novo Nordisk's Obesity Treatment Falls Short of Expectations	Dec. 20	MT
Jefferies Adjusts Amgen Price Target to $350 From $380, Maintains Buy Rating	Dec. 19	MT
Merck Strikes Deal With China's Hansoh Pharma to Develop Weight Loss Drug	Dec. 18	MT
Akari Therapeutics, plc Announces Board Changes	Dec. 18	CI
UBS Cuts Price Target on Amgen to $280 From $326, Maintains Neutral Rating	Dec. 17	MT
Amgen Inc. Announces Blincyto (Blinatumomab) Added to Chemotherapy Significantly Improves Survival in Newly Diagnosed Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (B-All)	Dec. 07	CI

Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other (5.8%): primarily royalties. The United States account for 70.3% of net sales.

Employees

26,700

Sector

Pharmaceuticals

Calendar

2025-02-04 - Q4 2024 Earnings Release

More about the company